Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein.
about
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") miceThe Synaptic Function of α-SynucleinC-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease.Neuroregeneration in neurodegenerative disorders.Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington's Disease: Exercise, Adenosine Receptors and AmpakinesNonaggregated α-synuclein influences SNARE-dependent vesicle docking via membrane binding.The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.RNA-Seq and human complex diseases: recent accomplishments and future perspectives.Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-synucleinAlpha-synuclein function and dysfunction on cellular membranes.Structural and dynamical insights into the membrane-bound α-synuclein.A GCase chaperone improves motor function in a mouse model of synucleinopathy.Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neuronsA critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficitsElevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synucleinAlpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway.Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.Parkinson's disease mouse models in translational research.Folding and misfolding of alpha-synuclein on membranes.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Oral biomarkers in exercise-induced neuroplasticity in Parkinson's disease.Knockdown of α-synuclein in cerebral cortex improves neural behavior associated with apoptotic inhibition and neurotrophin expression in spinal cord transected rats.Cell Biology and Pathophysiology of α-Synuclein.Determining nuclear localization of alpha-synuclein in mouse brains.Understanding the dynamics of monomeric, dimeric, and tetrameric α-synuclein structures in water.Prenatal activation of maternal TLR3 receptors by viral-mimetic poly(I:C) modifies GluN2B expression in embryos and sonic hedgehog in offspring in the absence of kynurenine pathway activation.Optogenetic Rescue of Locomotor Dysfunction and Dopaminergic Degeneration Caused by Alpha-Synuclein and EKO Genes.Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease.Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy.Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α-synuclein.AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers.Α-synuclein induces microglial cell migration through stimulating HIF-1α accumulation.
P2860
Q26859072-AA26B513-33A1-4229-B14B-7EBAEEE1471AQ27694711-0655C770-B3E9-4791-A656-F47DD3313757Q27931024-6BAF0D89-2D5A-46F1-B8F1-4964BC8FCD50Q31020342-0C1C2DF9-A902-4A0D-B35C-CF12E85AEDF6Q33705003-57824081-D371-480A-AE8B-9AD0A36C18DFQ33824692-284F37DE-1191-4068-AA3F-9D2363CE9242Q33991720-43BFC08D-8A4F-4087-ACE4-869D29670A48Q34284546-87D3E961-5F57-4B18-B26C-DE1DB99DC877Q34718257-689C20B7-7AAA-4F5B-890C-A19BF5ADCC77Q34774324-E59B4110-31FD-467A-8B4D-D09CA450F7EEQ35078181-BC5D5C4C-5C03-435C-B09D-583C80CF8EF4Q35340158-77542947-0551-4630-9944-EA470E8BC63CQ35728813-037D9E0C-1A54-4272-B060-D528AC77D9FDQ35951187-FD7B4669-3F8F-4377-920B-C4D5BC72E5F1Q36034871-88338F1A-D7CC-42A2-829F-BB6F839EDC38Q36585297-41D87973-0FE7-456E-9339-76B6767E38EBQ36999607-9A19DAD8-65C0-43E4-827B-D2042680E3F2Q37731940-07CDC634-8BD9-4950-966F-CE212D2C83A9Q37874160-3A8935D5-A517-4675-9AAD-4E2DB90C812CQ37938437-ADF537CB-16D8-4550-91D6-4FE8573542EFQ38541943-34290F06-5927-4E55-AEBD-46F1AC15DD69Q38733922-A40B8C76-D3DE-48B9-AC4B-F37C09352C86Q38914810-579712F7-C3C7-4BA6-A2D2-8C396E978132Q39097048-1E45D54D-E765-4BE0-BDD1-44C74865C676Q39788499-8EFDF5D0-354D-4890-B952-CD0310534C52Q41909087-B87F6A26-5B9B-4378-B62B-36807380BAA1Q42273974-D4E6FD85-109D-4B48-A14C-16B3CC27E81EQ42290602-2012DBFF-DA2A-4B84-8C35-1567653F503FQ46047010-CF2CAE1B-9068-4358-B599-14FAFA416D7FQ47826150-965E22AF-F91B-411C-8430-0E133DC1F3D8Q48157334-254A56CE-B784-4404-AEBD-5429031B0AE6Q48342632-21489085-1B69-47E7-871D-733D9107F126Q50279712-4A500256-ED2A-4368-8A10-50AF4D4C2912Q51162977-1297557D-04BF-4C4C-BDAE-D03753D828DF
P2860
Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alterations in corticostriatal ...... ressing human alpha-synuclein.
@en
Alterations in corticostriatal ...... ressing human alpha-synuclein.
@nl
type
label
Alterations in corticostriatal ...... ressing human alpha-synuclein.
@en
Alterations in corticostriatal ...... ressing human alpha-synuclein.
@nl
prefLabel
Alterations in corticostriatal ...... ressing human alpha-synuclein.
@en
Alterations in corticostriatal ...... ressing human alpha-synuclein.
@nl
P2093
P2860
P1433
P1476
Alterations in corticostriatal ...... ressing human alpha-synuclein.
@en
P2093
J B Watson
M S Levine
P2860
P304
P356
10.1016/J.NEUROSCIENCE.2009.01.021
P407
P577
2009-03-01T00:00:00Z